Compare AGIG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGIG | ATNM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 42.0M |
| IPO Year | N/A | 2013 |
| Metric | AGIG | ATNM |
|---|---|---|
| Price | $1.15 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 116.4K | 94.1K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.01 | $0.95 |
| 52 Week High | $5.31 | $1.95 |
| Indicator | AGIG | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 41.82 |
| Support Level | $1.04 | $0.99 |
| Resistance Level | $1.68 | $1.38 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 40.94 | 1.14 |
Abundia Global Impact Group Inc. is a technology solutions company operating in recycling, renewable energy, environmental change, fuels, and chemicals sectors, mainly focused on low-carbon energy solutions. The company uses waste plastics and biomass to produce crude or drop-in alternatives to fossil-derived energy, fuels, and chemicals through proprietary, licensed, and commercialized technologies, forming a complete process. It operates through its subsidiary and integrates feedstocks, technology, and off-take partners into a complete commercial chain. Its segments include Oil and Gas (O&G), which generates maximum revenue, and Renewables, which consists of its low-carbon fuels and renewable chemicals business.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.